Younger age was associated with worse locoregional recurrence–free survival, disease-free survival, and late DMFS, highlighting the importance of long-term monitoring and potential for personalized treatment approaches based on age, particularly for younger patients with ER-positive, ERBB2-negative breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.